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Summary
The human leukocyte antigen (HLA) complex, en-
compassing 3.5 Mb of DNA from the centromeric
HLA-DPB2 locus to the telomeric HLA-F locus on chro-
mosome 6p21, encodes a major part of the genetic pre-
disposition to develop type 1 diabetes, designated
“IDDM1.” A primary role for allelic variation of the
class II HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci
has been established. However, studies of animals and
humans have indicated that other, unmapped, major his-
tocompatibility complex (MHC)–linked genes are par-
ticipating in IDDM1. The strong linkage disequilibrium
between genes in this complex makes mapping a difficult
task. In the present paper, we report on the approach
we have devised to circumvent the confounding effects
of disequilibrium between class II alleles and alleles at
other MHC loci. We have scanned 12 Mb of the MHC
and flanking chromosome regions with microsatellite
polymorphisms and analyzed the transmission of these
marker alleles to diabetic probands from parents who
were homozygous for the alleles of the HLA-DRB1,
HLA-DQA1, and HLA-DQB1 genes. Our analysis, us-
ing three independent family sets, suggests the presence
of an additional type I diabetes gene (or genes). This
approach is useful for the analysis of other loci linked
to common diseases, to verify if a candidate polymor-
phism can explain all of the association of a region or
if the association is due to two or more loci in linkage
disequilibrium with each other.
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Introduction
Type 1 diabetes is a multifactorial disease, in which the
insulin-producing b cells of the pancreas are destroyed
by the immune system, a process determined by the ac-
tivity of major histocompatibility complex (MHC)–
restricted T lymphocytes. In humans and in animal mod-
els, it has been shown that the disease is genetically de-
termined, most profoundly by theMHCon chromosome
6p21 but also by a number of other loci throughout the
genome. The penetrance of this genetic program is in-
fluenced by as yet unidentified environmental factors
(Todd 1991). By association and ancestral haplotype
mapping, DNA sequencing, and functional studies,
MHC-linked susceptibility and resistance to type 1 di-
abetes (IDDM1; MIM 142857) has been fine mapped
to the MHC class II lociHLA-DQB1, HLA-DQA1, and
HLA-DRB1 (Todd et al. 1987). In parallel, the mouse
homologue has been mapped genetically and biologi-
cally to the homologues of HLA-DQ and HLA-DR, the
IA and IE loci in the murine MHC (Ikegami et al. 1995;
Wicker et al. 1995). It is likely that the T lympho-
cyte–mediated destruction of b cells is governed by the
highly polymorphic peptide-binding properties of HLA
class II alleles. The vast majority of these polymorphisms
are encoded by a single exon, exon 2 of the homologous
class II genes. However, it is clear from studies in mice
(Ikegami et al. 1995), and it has also been suggested by
studies in humans (Thomsen et al. 1988; Risch 1989;
Caplen et al. 1990; Nakanishi et al. 1993; Robinson et
al. 1993; Fennessy et al. 1994; Fujisawa et al. 1995; Tait
et al. 1995; Erlich et al. 1996) that sequence variation
within exon 2 of these genes cannot explain all of the
association of the MHC region with type 1 diabetes.
Certain MHC haplotypes are differentially associated
with disease even though the class II exon sequences are
the same (Risch 1989; Langholz et al. 1995). Owing to
linkage disequilibrium among loci, particularly on cer-
tain haplotypes such as the A1-B8-DR3 haplotype, it
has been difficult to detect and even more difficult to
map the additional effects outside the HLA class II exon
2 sequences.
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Robinson et al. (1993) analyzed extended MHC hap-
lotypes by using sib pairs affected with type 1 diabetes
with parents homozygous for class II alleles. Their anal-
ysis suggested the presence of one or more additional
disease loci by analyzing the presence of linkage in the
region when the contribution from HLA-DRB1 was
fixed. We have now extended the homozygous-parent
test by using the transmission/disequilibrium test (TDT)
to evaluate the disease association of marker alleles of
microsatellite polymorphisms across 12 Mb of chro-
mosome 6p21, including the MHC and the hemochro-
matosis (HFE) gene region. Such a study has only be-
come feasible recently, owing to the availability of DNA
samples from very large numbers of families with type
1 diabetic children that have been HLA class II typed
and to the characterization of several polymorphic mi-
crosatellites in the MHC and HFE regions. We present
evidence for a second disease locus linked to, but distinct
from, the classic HLA class II loci. Allele 3 of marker
D6S2223, 5.5 Mb telomeric of the class II region, was
strongly associated with type 1 diabetes (Pcorrected [Pc] 
.0001). We cannot locate the etiological variant with any
precision, but it is possible that the non–HLA class II
locus is closer to the HFE locus, 8.5 Mb distal to the
HLA class II loci, than to the classically defined MHC.
Subjects and Methods
Subjects
The regional committee for ethics in medical research
in Norway approved this study. Families were selected
from large data sets from Norway (526 families), Den-
mark (147 families), and the United Kingdom (333 fam-
ilies) that were used in previous studies (Undlien et al.
1995; Delepine et al. 1997; Merriman et al. 1997). To
exclude associations secondary to linkage disequilibrium
with already established high-risk HLA-DRB1, HLA-
DQA1, and HLA-DQB1 alleles during TDT analysis,
all families selected to enter this study had at least one
parent who was homozygous for HLA-DRB1, HLA-
DQA1, and HLA-DQB1 alleles. It is important to note
that homozygosity is also required for specific HLA-
DRB1*04 subtypes because this amino acid variation
(encoded by exon 2) has an important role in type 1
diabetes (Sheehy et al. 1989; Cucca et al. 1995; Undlien
et al. 1997a). These inclusion criteria resulted in a group
of 100 Norwegian families, 51 Danish families, and 74
U.K. families for study. Of these 225 families, there
were 116 DRB1*03-DQA1*0501-DQB1*0201 and 51
DRB1*0401-DQA1*03-DQB1*0302 homozygous par-
ents; for other DRB1-DQA1-DQB1 haplotypes, the
number of homozygous parents was small ( ). Thisn ! 11
demonstrates a limitation of the approach, in that only
alleles that are common can be evaluated, because only
a few families have parents homozygous for haplotypes
other than DR3 and DR4. Only one diabetic offspring
from each family was included in the TDT analysis to
make it a valid test for association. In multiplex families,
the first child diagnosed was chosen. The Norwegian
data set contained families with one child with type 1
diabetes diagnosed at age !15 years. In the families from
Denmark, all affected children were diagnosed at age
!20 years (Delepine et al. 1997). The U.K. families were
restricted to whites with grandparents born in the United
Kingdom, and the proband was given a diagnosis at age
!17 years (Bain et al. 1990). The Norwegian and Danish
family studies also consisted of DNA samples from sib-
lings healthy (i.e., nondiabetic) at the time of sample
collection.
The case-control sets consisted of 228 subjects with
type 1 diabetes and 362 controls, who were either
DRB1*03-DQA1*0501-DQB1*0201/DRB1*04-
DQA1*03-DQB1*0302 heterozygotes, DRB1*03-
DQA1*0501-DQB1*0201 homozygotes, or DRB1*04-
DQA1*03-DQB1*0302 homozygotes. The subjects
were recruited from pediatric departments throughout
Norway during the period 1992–96, and they were all
aged !15 years at disease onset. The controls were se-
lected from the Norwegian Bone Marrow Donor Reg-
istry. Both cases and controls originated from the rela-
tively ethnically homogeneous Norwegian population.
Parts of this material have been used previously in stud-
ies on the contribution of DR4 subtypes (Undlien et al.
1997a), HLA class II large multifactorial protease poly-
morphisms (Undlien et al. 1997b), and HLA-DPA1 and
HLA-DPB1 alleles (Lie et al. 1997) to type 1 diabetes
susceptibility. A few samples were not typed for all mark-
ers, owing to either PCR failure (excluded when PCR
failed three times) or lack of DNA.
Genomic HLA Typing
Typing forHLA-DQA1, HLA-DQB1, and DRB1*04
subtypes was performed as described elsewhere (Undlien
et al. 1997a). Sixteen microsatellite markers (dinucleo-
tide repeats), spanning from ∼2.5 Mb centromeric to
∼8.5 Mb telomeric of the HLA class II region, were
selected, mainly from the article by Feder et al. (1996).
In the first microsatellite-marker scan in the families, we
included the following microsatellite markers: D6S291,
DQCAR, D6S273, D6S265, D6S2222, D6S2223,
D6S2239, and D6S2235; in the second step, we ana-
lyzed D6S306, D6S1001, D6S105, D6S464, D6S2225,
D6S2219, D6S1260, and D6S1558. Primer sequences
were obtained from the Genome Database (GDB). PCR
products were separated on a 4.25% urea-polyacryl-
amide gel and were identified according to size, on an
ABI 377 DNA sequencer. The alleles at each microsat-
ellite were given a numerical value (1, 2, 3, 4, etc.),
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Table 1







D6S2223 (ALLELE 3) D6S273 (ALLELE 2)
T NT %T (CI) x2 Pnc T NT %T (CI) x
2 Pnc
Total:
Probandwise 9 37 20 (8–32) 17.0 .00004 21 5 81 (66–96) 9.8 .002
Healthy siblings 16 20 44 (28–60) .4 NS 6 6 50 (22–78) .0 NS
Norway:
Probandwise 5 15 25 (6–44) 5.0 .03 9 1 90 (71–100) 6.4 .01
Healthy siblings 12 15 44 (25–63) .3 NS 5 6 45 (16–74) .1 NS
Denmark:
Probandwise 1 7 13 (0–36) 4.5 .03 5 1 83 (53–100) 2.7 NS
Healthy siblings 4 5 44 (12–76) .1 NS 1 0 ) 1.0 NS
United Kingdom:
Probandwise 3 15 17 (0–34) 8.0 .005 7 3 70 (42–98) 1.6 NS
NOTE.—Allele 3 at D6S2223 and allele 2 at D6S273 from DRB1*03-DQA1*0501-DQB1*0201homozygous
parents in the individual data sets of type 1 diabetes families from Norway, Denmark, and the United Kingdom.
T  no. transmitted, NT  no. not transmitted, and NS  not significant.
starting at the allele with the fewest number of base
pairs. In some instances, this value was not in agreement
with the GDB terminology.
Statistical Methods
Initially, we tested the microsatellites by TDT in three
independent family data sets, in which at least one parent
per family was homozygous at the HLA class II loci
HLA-DRB1, HLA-DQA1, and HLA-DQB1. Only al-
leles with a frequency 15% and with 20 informative
meiosis in the total data set were included. The TDT
analyzes whether transmission of an allele, from parents
heterozygous for the marker tested to the proband, de-
viates from the expected 50% (Spielman et al. 1993)
and gives a x2 test statistic with 1 df. Confidence intervals
(95% [CI]) for the percentage transmission (%T) of al-
leles were calculated by application of the formula
, in which p denotes the pro-CI %T 1.96 [p(1-p)/n]
portion of positive transmissions and n denotes the total
number of transmissions. Only transmissions from
HLA-DRB1, HLA-DQA1, and HLA-DQB1 homozy-
gous parents were included in the analysis, to exclude
secondary effects resulting from linkage disequilibrium
with high-risk HLA-DRB1, HLA-DQA1, and HLA-
DQB1 alleles. We refer to this test as the “homozygous-
parent TDT.” The transmissions from HLA-DRB1,
HLA-DQA1, and HLA-DQB1 homozygous parents
were evaluated separately for different HLA class II hap-
lotypes, because an association might emerge differently
on distinct haplotypes or may even be haplotype depen-
dent. The SIMCROSS program was used to estimate
haplotypes (Weeks et al. 1995), and then manual in-
spection of pedigrees was performed.
We compared the allele frequencies among subjects
and controls using x2 analysis or Fisher’s exact test when
appropriate. Subjects were grouped according to HLA-
DRB1, HLA-DQA1, and HLA-DQB1 genotypes (in-
cluding HLA-DRB1*04 subtypes) and were tested for
association separately, to exclude secondary associations
resulting from linkage disequilibrium with these high-
risk alleles.
Linkage disequilibrium between markers was calcu-
lated as normalized values of either pairwise disequilib-
rium statistics (D′) or global disequilibrium statistics
(Wn) (Klitz et al. 1995). Both values show a range of
from 1 to 1 (representing complete disequilibrium [1]
to complete equilibrium [0] to never occurring on the
same haplotype [1]). All parental haplotypes were used
in these calculations.
Results
Initially, eight microsatellite markers, spanning from
∼2.5 Mb centromeric to ∼5.5 Mb telomeric of the HLA
complex, were tested with the homozygous-parent TDT
in the selected 225 families. Allele 3 ofD6S2223 showed
association with disease after correction for the total
number of alleles tested ( ; [see table 1n  25 P  .001c
and fig. 1a]) in the 116 DRB1*03-DQA1*0501-
DQB1*0201 homozygous-parent families. Marker
D6S2223 is located ∼5.5 Mb telomeric of HLA class II
and ∼1.5 Mb centromeric of the HFE locus (fig. 1a).
Linkage disequilibrium was strong between HLA class
II (DQCAR) and D6S2223 ( , , 48 df,2W  .49 x  720n
). The reduced transmission of allele 3 to pro-P K .001
bands was consistent in all three populations studied
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Figure 1 TDT from DRB1*03-DQA1*0501-DQB1*0201 homozygous parents, for all microsatellites analyzed in this study, presented
for the total family data set (from Norway, Denmark, and the United Kingdom). Both the x2 test statistics and %T of positively (denoted by
unhatched bars and doted lines) and negatively (denoted by hatched bars and solid lines) associated alleles are shown. The location of nearby
genes is outlined, and the distances are approximate; n  no. of informative meiosis for each marker allele. a, Microsatellites analyzed in the
initial screen covering ∼12 Mb. The positively and negatively transmitted alleles presented are the following: allele 3 ( ) and allele 2n  53
( ) at D6S291, allele 2 ( ) and allele 7 ( ) at D6S273, allele 1 ( ) and allele 5 ( ) at D6S265, allele 3 ( )n  47 n  26 n  48 n  18 n  27 n  55
and allele 2 ( ) at D6S2222, allele 2 ( ) and allele 3 ( ) at D6S2223, allele 2 ( ) and allele 3 ( ) at D6S2239, andn  50 n  24 n  45 n  39 n  57
allele 4 ( ) and allele 2 ( ) at D6S2235. Only a few DRB1-DQA1-DQB1 homozygous parents were heterozygous for DQCAR,n  50 n  46
and there was no biased transmission. Only alleles with are still significant after correction for multiple tests (25 alleles). b, More2x 1 9.1
densely spaced markers in 900-kb region flanking marker D6S2223. The most negatively transmitted alleles for the additional markers are
presented. These are as follows: allele 6 ( ) at D6S306, allele 11 ( ) at D6S1001, allele 10 ( ) at D6S105, allele 10 ( )n  61 n  51 n  27 n  59
at D6S464, allele 5 ( ) at D6S2225, allele 3 ( ) at D6S2219, allele 4 ( ) at D6S1260, and allele 1 ( ) at D6S1558.n  53 n  56 n  54 n  22
(20% transmission overall). Importantly, transmission
to unaffected siblings was not different from 50%
(table 1).
One other allele, allele 2 of marker D6S273, located
between TNF and HSP70 (D’Alfonso and Richiardi
1996), showed some evidence for nonrandom transmis-
sion from DRB1*03-DQA1*0501-DQB1*0201 homo-
zygous parents (81% T, ; table 1). This markerP  .05c
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Table 2
Case-Control Analysis of D6S2223 and D6S273
DRB1-DQB1
GENOTYPES
D6S2223 (ALLELE 3) D6S273 (ALLELE 2)
Patients (%) Controls (%) Pnc Patients (%) Controls (5) Pnc
03-0201/03-0201 38 (66) 119 (80) .03 5 (8.6) 5 (3.5) NS
03-0201/0401-0302 167 (67) 163 (73) NS 16 (6.5) 6 (2.6) .04
03-0201/0404-0302 48 (80) 141 (71) NS 7 (11.7) 9 (4.5) NS
0401-0302/0401-0302 27 (56) 27 (68) NS 2 (4.2) 0 NS
0401-0302/0404-0302 18 (90) 30 (75) NS 4 (20) 0 .01
NOTE.—Only the DRB1-DQA1-DQB1 genotype groups with more than five individuals among
both cases and controls are included. NS  not significant.
has been reported previously to be associated with type
1 diabetes in a Belgian case-control study (Moghaddam
et al. 1998). In contrast to our results, Moghaddam and
colleagues found allele 2 (130 bp) on the DRB1*03 hap-
lotype to be less frequent (although not significantly)
among patients. They observed a negatively associated
allele atD6S273 (140 bp), which was equally distributed
among subjects and controls (both independent control
subjects and family-based ones) in our data sets. This
allele is not in linkage disequilibrium with allele 3 at
D6S2223 ( , ).′D  .07 P  .02
To extend support for the disease association observed
for allele 3 at D6S2223 and for allele 2 at D6S273, we
analyzed these two marker alleles in an independent and
completelyHLA-DRB1, HLA-DQA1, andHLA-DQB1
matched Norwegian case-control set (table 2). Allele 3
atD6S2223 was found with decreased frequency among
DRB1*03-DQA1*0501-DQB1*0201 homozygous sub-
jects , compared with DRB1*03-DQA1*0501-
DQB1*0201 homozygous controls (P  .03, Pc  .27),
which is consistent with the observations from all three
family data sets. Allele 2 at D6S273 had increased fre-
quencies in heterozygous subjects carrying either the ge-
notype DRB1*0401-DQA1*03-DQB1*0302/
D R B 1 * 0 3 - D Q A 1 * 0 5 0 1 - D Q B 1 * 0 2 0 1
(P  .04, Pc  .36) or DRB1*401-DQA1*03-
D Q B 1 * 0 3 0 2 / D R B 1 * 0 4 0 4 - D Q A 1 * 0 3 -
DQB1*0302 (P .01, Pc .09), compared withDRB1-
DQA1-DQB1 matched controls.
We wanted to test whether the associations with
D6S2223 and D6S273 were independent from or a re-
sult of linkage disequilibrium between alleles of the two
markers. The global disequilibrium statistic between
D6S273 and D6S2223 was ( , 32 df,2W  .27 x  222n
). When the TDT was applied only to parentsP K .001
homozygous for DRB1*03-DQA1*0501-DQB1*0201
and alleles atD6S273, the disease association with allele
3 at D6S2223 was even stronger (15%T, P  .002, Pc
 .004). For allele 2 of D6S273, the disease association
was slightly reduced when the parents were homozygous
for both class II and D6S2223 (71%T, P  ns). Some
degree of negative linkage disequilibrium between allele
3 at D6S2223 and allele 2 at D6S273 exists ( ′D  
, )..4 P  .003c
To evaluate the extent of the associated region con-
taining marker D6S2223, we analyzed a much more
densely spaced set of polymorphic markers, spaced an
average of every 100 kb and covering ∼400 kb and ∼500
kb of DNA centromeric and telomeric, respectively, of
D6S2223. The linkage disequilibrium values between
the adjacent microsatellites are as follows (calculated by
Wn): D6S2222–(.41)–D6S306–(.43)–D6S1001–(.35)–
D6S105– (.41)–D6S464– (.60)–D6S2223– (.30) –
D6S2225 – ( .16) –D6S2219 – ( .34) –D6S1260 –
(.34)–D6S1558, and all . Negative transmis-P K .001
sion of a marker allele to diabetic probands from
DRB1*03-DQA1*0501-DQB1*0201 homozygous par-
ents, observed with D6S2223, was also observed for
allele 5 ofD6S2225 (37%T, , ), the closestP  .05 P  1c
marker to D6S2223.
No significant biased transmission of alleles from
other HLA-DRB1, HLA-DQA1, and HLA-DQB1 ho-
mozygous parents (not DRB1*03-DQA1*0501-DQB-
1*0201) were observed ( ; data not shown). Fi-n  107
nally, the paternal and maternal transmissions to
probands were analyzed separately, but no heterogeneity
was observed (data not shown).
Discussion
The homozygous-parent TDT is a new approach for
fine mapping of disease-linked chromosome regions.
Our data for MHC in type 1 diabetes suggest that there
is at least one additional component outside exon 2 of
HLA-DRB1, HLA-DQA1, and HLA-DQB1. Allele 3
ofD6S2223 appears to be in linkage disequilibriumwith
an allele at a locus that affects the etiology of type 1
diabetes on DRB1*03-DQA1*0501-DQB1*0201 hap-
lotypes. This conclusion is supported by inP  .001c
families, with the same trend shown in a second inde-
pendent HLA class II–matched case-control data set
( ). Our data are consistent with previous esti-P  .27c
mates by Robinson et al. (1993) that 40% of DR3 hap-
lotypes confer a significantly higher risk than other DR3
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haplotypes, by use of the homozygous-parent af-
fected–sib pair method. Nevertheless, the result has to
be confirmed in further data sets.
Results of a case-control study that suggested an as-
sociation between marker D6S273 and type 1 diabetes
were reported recently (Moghaddam et al. 1998). We
also found some evidence for an association forD6S273
by using the homozygous-parent TDT with allele 2, con-
ferring disease susceptibility on the DRB1*03-
DQA1*0501-DQB1*0201 haplotype. Moghaddam et
al. (1998) found this allele (130 bp) to provide suscep-
tibility on the DRB*0401 haplotype, whereas on the
DRB1*03 haplotype it showed a nonsignificant ten-
dency of being protective. In our case-control study, al-
lele 2 appeared at a higher frequency in all patient
groups, subdivided by class II haplotypes, compared
with controls, but only provided association at P ! .05
in the DRB1*03 homozygous and DRB1*0401/
DRB1*0404 heterozygous individuals. Therefore, our
results for allele 2 at D6S273 are partly consistent with
the study by Moghaddam et al. (1998). However, the
associations they detected for other alleles at D6S273
were not replicated in our analyses.
The fact that no biased transmission to healthy sib-
lings was observed in the Danish andNorwegian families
(table 1) strongly supports the validity of the homozy-
gous-parent TDT and of our conclusions, and it also
rules out segregation distortion as an explanation for
the associations observed with type 1 diabetes. The ob-
servation of linkage disequilibrium between class II and
D6S2223, separated by 5.5 Mb of DNA, shows the ne-
cessity of controlling for DRB1-DQA1-DQB1 by use
of the homozygous-parent TDT, even for markers lo-
cated far from the known etiological loci.
The DRB1*03-DQA1*0501-DQB1*0201 haplotype
was the most frequent among ourDRB1-DQA1-DQB1
homozygous parents (52%) and was the only haplotype
for which we detected nonrandom transmission of mi-
crosatellite-marker alleles. The lack of association for
otherDRB1-DQA1-DQB1 haplotypes could be because
of insufficient sample size or because the effect of the
additional gene(s) may only occur on DRB1*03-
DQA1*0501-DQB1*0201 haplotypes. The limitation of
the homozygous-parent TDT is that only DR-DQ hap-
lotypes with high risk to develop the disease are present
in sufficiently high frequencies to make them useful for
statistical analyses. Only parents homozygous for the
established or suspected disease alleles are informative
in this test.
Although our results indicate the presence of another
gene(s) outside the HLA class II region, we cannot map
its location. The problem with linkage-disequilibrium
mapping is that the association of a marker with disease
does not necessarily reflect its proximity to the etiolog-
ical locus, because the distribution of marker alleles on
predisposing and nonpredisposing chromosomes is un-
predictable. However, each of the markers used in this
study have been shown to be in linkage disequilibrium
with its adjacent markers. Therefore, given the fact that
no microsatellites flanking D6S2223 showed any asso-
ciation in the homozygous-parent TDT, the most likely
location of the proposed and novel type 1 diabe-
tes–involved gene in linkage disequilibrium with
D6S2223 would be telomeric of HLA-F, in the vicinity
of D6S2223. The HLA-A gene, which has been pro-
posed by others to be involved in type 1 diabetes (Nak-
anishi et al. 1993), is 2.8-Mb centromeric of D6S2223,
but our results do not point to this locus. This does not
mean that there is no separate association at this locus
but simply that it could not be detected by use of the
microsatellite markers evaluated in the present study.
Moreover, we cannot formally rule out that the second
locus is within the class II region itself, outside the exon
2 sequences.
How can the putative etiological determinant near
D6S2223 be mapped? D6S2223-defined haplotypes
could be further characterized by use of a dense set of
microsatellites and single-nucleotide polymorphisms
(SNPs) around the associated marker. This would enable
us to define ancestral chromosome segments shared iden-
tical-by-descent between nonpredisposing D6S2223 al-
lele 3–positive haplotypes that are distinct from those
of other haplotypes showing no association (“cross-
match” haplotype mapping) (Todd et al. 1987, 1989;
Degli-Esposti et al. 1992; Bennett and Todd 1996). It
will be possible to identify ancient recombination break-
points that should yield fine-mapping information. We
can also analyze the association of haplotype segments
in different populations, such as Asian, African, and Sar-
dinian, in the same way these populations were used to
map the class II loci as etiological determinants (Todd
et al. 1989; Sheehy et al. 1989; Cucca et al. 1995). Per-
haps the most productive way to proceed is to search
all known genes in linkage disequilibriumwithD6S2223
for SNPs, to test each as a candidate that might explain
the association of D6S2223. Candidate polymorphisms
that have allele distributions consistent with the hap-
lotype associations described here will be studied for
functional activity. With an ongoing worldwide effort to
identify very large numbers of common SNPs and emerg-
ing technology for typing SNPs, use of this approach
with every gene in the MHC should become feasible in
the near future. A combination of genetic and functional
analysis, as used for the identification of IDDM1 and
IDDM2, will be necessary, as well as continued analysis
of the mouse and rat models of disease.
In conclusion, this study provides consistent evidence
for at least one novel diabetes gene other than those
defined by the exon 2 polymorphism of theHLA-DRB1,
HLA-DQA1, and HLA-DQB1 loci. Our data provide
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consistent evidence for linkage and association to
marker D6S2223, located 5.5 Mb telomeric of the HLA
class II region. IDDM1 appears to be a cluster of linked
disease determinants. Clustering of separate disease loci
in regions defined by a single peak of linkage may be
characteristic of common diseases caused by low-pene-
trance alleles at multiple loci. In the spontaneous mouse
model of type 1 diabetes, we now know that a linkage
peak on chromosome 3 comprises at least four separate
disease loci (Podolin et al. 1998). The possibility of mul-
tiple closely linked disease loci makes the prospect for
their identification even more challenging, particularly
in outbred human populations. The homozygous-parent
TDT can be a useful tool for this purpose.
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